Sale, closing of the factory ... Multinational drug companies collectively adjust global research and development pipeline, heavy gold bet on this wind

In 2014, some of Novartis's vaccine program, purchased by GSK through a "changeof" deal, was sold!On October 21st GSK has agreed to sell Rabipur /Rabavert vaccines for rabies, the tick brain vaccine and encepur (TB E vaccine) to Bavarian Nordic companies in an effort to scale back the development pipeline and focus more on oncology and immunology, According to Endpoints NewsThe deal is worth nearly $1.1 billion and $336 million in advancethe source of the vaccine program is part of the Novartis vaccine business that GSK acquired in 2014 for $5.25 billion in cash and a subsequent $1.8 billion patent feesell, spin-off, slimback, transform, multinational pharmaceutical giants have never had the key wordsRecently, in addition to GSK, Mersadong, Roche and so on have also adjusted the global research and development pipeline, through the sale, cut in research projects and other ways to focus on the core areasBut it's worth noting that the big wigs are also focusing on the field of biologicseight of the world's top 10 best-selling drugs in 2018 are biologics, including seven antibody drugs and one vaccine productThe global biopharmaceutical market has grown rapidly in recent years, but growth will continue in the future, with the global biopharmaceutical market growing further to $327.6 billion by 2020GSK cut and sell multiple vaccine projects
2019 is certainly an exciting year for GSK's vaccine businessGSK's heavy shingrix vaccine, which has been a huge success since it was approved by the FDA in 2017, has gained a rapid share of the market for zostavax, the veteran shingles vaccine, and generated nearly $1 billion in sales in the first half of 2019Shingrix has been "out of stock" because of its booming demand, with GSK only imposing order restrictionsafter EvaluatePharma predicted that GSK would be the market leader in vaccines in 2024, with sales of more than $10 billion and a 24.1 percent market share, followed by Merck and Co, Sanofi and PfizerDespite this, GSK does not seem to be focusing on the vaccine businessIn May, GSK did not hesitate to cut off two other vaccine programs in an assessment, one for streptococcus pneumonia and one for universal flu vaccinesEmma Walmsley, gSK's chief executive, said: "Looking at the early data, we don't think this is a project worth moving forward with We are very strict on this point and we will continue to push ahead with a fairly aggressive plan to stop assets when needed and double our bets and it is understood that since Emma Walmsley became chief executive in 2017 and Hal Barron took over the long-struggling research and development division in 2018, this relentless insistence on data has become commonplace at GSK new leadership is trying to screen the pharmaceutical giant's product line to refocus on core assets and complement its research and development capabilities through acquisitions In December, GSK bought Tesaro, the Us cancer drug maker, for $5.1 billion, including zejula, the latter's PARP inhibitor, and drugs that inhibit PD-1, TIM-3 and LAG-3 checkpoints Investors were shocked by the biggest drop in GSK's share price in a decade, but Hal Barron said the deal was important to GSK's faltering research and development pipeline GSK has cut 11 projects it had planned to do in preparation for the acquisition of Tesaro, hal Barron said: "We didn't get involved in projects that were more valuable and interesting than the 11 projects." "Even less than two years into his tenure, Hal Barron has embraced the "bloody" cut in its product line since then, GSK has also cut jobs, cutting down an Ebola vaccine and two respiratory drugs, while making a multimillion-dollar bet on Lyell, a cell therapy start-up whose goal is to treat solid tumors GSK also hired cancer specialists from Merck, Novartis, AstraZeneca and others to work with 23andMe and CRISPR-Cas9 pioneers, with the goal of reshaping the pharmaceutical industry's drug targets It can be seen that GSK hopes to achieve a major breakthrough in the field of cancer and immunity focus on K-drug, Mersadon launched a new round of big layoffs
under the impact of GSK's Shingrix, The Moshadon's old shingle herpes vaccine Zepatier was hit hard, with revenues falling more than 72 percent to $455 million in 2018 from $1.66 billion in 2017 Meanwhile, in fiscal 2018, Mercadon's full-year preparation revenue was $37.689 billion, with Keytruda contributing $7.171 billion analysts are already taking key to The AbbVie's Humira as the best-selling drug and expect selling $10 billion by the end of 2019 EvaluatePharma predicts that Keytruda will become the industry's top drug by 2024, with annual sales of $17 billion to focus more on innovation and research and development and seize the growth opportunities of Mersadon, which announced a massive layoff that will cut about 500 jobs in several U.S states from January 3, 2020 A spokesman for Mercado said the job cuts would affect some of the sales and head office business teams, and that Messadon is adding U.S jobs in growth areas such as oncology it's not hard to see that at a time when cancer drugs have become the engine of Mercado's development, focusing more of its resources on Keytruda and other cancer-heavy drugs is the purpose of the cuts in fact, as early as Keytruda was still in the clinical trial phase, Mersadon had to focus resources, go all out to promote the Keytruda clinical trial and cut off the remaining in-research projects, and eventually K drugs can be a disadvantage in the market time, relying on clinical trial data to catch up with O drugs, and later came to the top Roche's biopharmaceutical sector, closing four small molecular drug plants
foreign media outlet FiercePharma reported that Roche may close its small molecular drug plant in Ireland next year and lay off 132 workers and shortly before that, Roche had sold three small molecular drug plants in the US, Italy and Spain, and the Irish plant had to close because it had not found a suitable buyer In the case of the dismissals of 132 workers, Roche has set aside up to 24 million euros in severance payments, with each employee receiving an average of up to 180,000 euros, or more than 1.4 million yuan the "troika" of boff-beads, quto-bead mono-resistance, and ritoxian resistance, which have brought in substantial revenues for Roche, have been threatened by biosimilars around the world Back in 2015, Roche announced plans to transform itself to reduce small molecule manufacturing capacity and increase the production capacity of biologics It comes after Roche announced it would spend 800 million euros to expand biopharmaceutical production at its plants in Germany, Switzerland and the United States As part of the transformation plan, Roche said it would cut 1,200 jobs and sell four small molecular sites around the world The Irish plant is the last of four small molecular bases This underscores Roche's determination to transition to biologics in 2009, Roche bought Genetech for $46.8 billion and acquired three heavy anti-tumor drugs, which made Roche a huge profit and established Roche's position in the biopharmaceutical sector Today, eight of the world's heavy-duty bomb-bomb drugs, TOP10, are biologics, and Roche continues to add to the field of biopharmaceuticals by slimming down As an era-long breakthrough in the exploration of disease treatment, biologics will also lead the innovation drug industry for a long time original title: Sell, stop research and development projects, close factories, lay off workers.. Multinational drug companies collectively adjust global research and development pipeline, heavy gold bet on this wind